1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Metastatic Non-small Cell Lung Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Metastatic Non-small Cell Lung Cancer Market, by Histology
8.1.1. Adenocarcinoma
8.1.1.1. Market Revenue and Forecast
8.1.2. Squamous Cell Carcinoma
8.1.2.1. Market Revenue and Forecast
8.1.3. Large Cell Carcinoma
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Metastatic Non-small Cell Lung Cancer Market, by Treatment Type
9.1.1. Chemotherapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Targeted Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Immunotherapy
9.1.3.1. Market Revenue and Forecast
9.1.4. Combination Therapy
9.1.4.1. Market Revenue and Forecast
9.1.5. Radiotherapy/Others
9.1.5.1. Market Revenue and Forecast
10.1. Metastatic Non-small Cell Lung Cancer Market, by Drug Class
10.1.1. PD-1/PD-L1 Inhibitors
10.1.1.1. Market Revenue and Forecast
10.1.2. EGFR Inhibitors
10.1.2.1. Market Revenue and Forecast
10.1.3. ALK/ROS1/RET Inhibitors
10.1.3.1. Market Revenue and Forecast
10.1.4. Antibody-Drug Conjugates (ADCs)
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Metastatic Non-small Cell Lung Cancer Market, by Line of Therapy
11.1.1. First-Line Therapy
11.1.1.1. Market Revenue and Forecast
11.1.2. Second-Line Therapy
11.1.2.1. Market Revenue and Forecast
11.1.3. Third-Line & Later
11.1.3.1. Market Revenue and Forecast
12.1. Metastatic Non-small Cell Lung Cancer Market, by Distribution Channel
12.1.1. Hospital Pharmacy
12.1.1.1. Market Revenue and Forecast
12.1.2. Retail Pharmacy
12.1.2.1. Market Revenue and Forecast
12.1.3. Online Pharmacy
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Histology
13.1.2. Market Revenue and Forecast, by Treatment Type
13.1.3. Market Revenue and Forecast, by Drug Class
13.1.4. Market Revenue and Forecast, by Line of Therapy
13.1.5. Market Revenue and Forecast, by Distribution Channel
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Histology
13.1.6.2. Market Revenue and Forecast, by Treatment Type
13.1.6.3. Market Revenue and Forecast, by Drug Class
13.1.6.4. Market Revenue and Forecast, by Line of Therapy
13.1.6.5. Market Revenue and Forecast, by Distribution Channel
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Histology
13.1.7.2. Market Revenue and Forecast, by Treatment Type
13.1.7.3. Market Revenue and Forecast, by Drug Class
13.1.7.4. Market Revenue and Forecast, by Line of Therapy
13.1.7.5. Market Revenue and Forecast, by Distribution Channel
13.2. Europe
13.2.1. Market Revenue and Forecast, by Histology
13.2.2. Market Revenue and Forecast, by Treatment Type
13.2.3. Market Revenue and Forecast, by Drug Class
13.2.4. Market Revenue and Forecast, by Line of Therapy
13.2.5. Market Revenue and Forecast, by Distribution Channel
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Histology
13.2.6.2. Market Revenue and Forecast, by Treatment Type
13.2.6.3. Market Revenue and Forecast, by Drug Class
13.2.7. Market Revenue and Forecast, by Line of Therapy
13.2.8. Market Revenue and Forecast, by Distribution Channel
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Histology
13.2.9.2. Market Revenue and Forecast, by Treatment Type
13.2.9.3. Market Revenue and Forecast, by Drug Class
13.2.10. Market Revenue and Forecast, by Line of Therapy
13.2.11. Market Revenue and Forecast, by Distribution Channel
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Histology
13.2.12.2. Market Revenue and Forecast, by Treatment Type
13.2.12.3. Market Revenue and Forecast, by Drug Class
13.2.12.4. Market Revenue and Forecast, by Line of Therapy
13.2.13. Market Revenue and Forecast, by Distribution Channel
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Histology
13.2.14.2. Market Revenue and Forecast, by Treatment Type
13.2.14.3. Market Revenue and Forecast, by Drug Class
13.2.14.4. Market Revenue and Forecast, by Line of Therapy
13.2.15. Market Revenue and Forecast, by Distribution Channel
13.3. APAC
13.3.1. Market Revenue and Forecast, by Histology
13.3.2. Market Revenue and Forecast, by Treatment Type
13.3.3. Market Revenue and Forecast, by Drug Class
13.3.4. Market Revenue and Forecast, by Line of Therapy
13.3.5. Market Revenue and Forecast, by Distribution Channel
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Histology
13.3.6.2. Market Revenue and Forecast, by Treatment Type
13.3.6.3. Market Revenue and Forecast, by Drug Class
13.3.6.4. Market Revenue and Forecast, by Line of Therapy
13.3.7. Market Revenue and Forecast, by Distribution Channel
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Histology
13.3.8.2. Market Revenue and Forecast, by Treatment Type
13.3.8.3. Market Revenue and Forecast, by Drug Class
13.3.8.4. Market Revenue and Forecast, by Line of Therapy
13.3.9. Market Revenue and Forecast, by Distribution Channel
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Histology
13.3.10.2. Market Revenue and Forecast, by Treatment Type
13.3.10.3. Market Revenue and Forecast, by Drug Class
13.3.10.4. Market Revenue and Forecast, by Line of Therapy
13.3.10.5. Market Revenue and Forecast, by Distribution Channel
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Histology
13.3.11.2. Market Revenue and Forecast, by Treatment Type
13.3.11.3. Market Revenue and Forecast, by Drug Class
13.3.11.4. Market Revenue and Forecast, by Line of Therapy
13.3.11.5. Market Revenue and Forecast, by Distribution Channel
13.4. MEA
13.4.1. Market Revenue and Forecast, by Histology
13.4.2. Market Revenue and Forecast, by Treatment Type
13.4.3. Market Revenue and Forecast, by Drug Class
13.4.4. Market Revenue and Forecast, by Line of Therapy
13.4.5. Market Revenue and Forecast, by Distribution Channel
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Histology
13.4.6.2. Market Revenue and Forecast, by Treatment Type
13.4.6.3. Market Revenue and Forecast, by Drug Class
13.4.6.4. Market Revenue and Forecast, by Line of Therapy
13.4.7. Market Revenue and Forecast, by Distribution Channel
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Histology
13.4.8.2. Market Revenue and Forecast, by Treatment Type
13.4.8.3. Market Revenue and Forecast, by Drug Class
13.4.8.4. Market Revenue and Forecast, by Line of Therapy
13.4.9. Market Revenue and Forecast, by Distribution Channel
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Histology
13.4.10.2. Market Revenue and Forecast, by Treatment Type
13.4.10.3. Market Revenue and Forecast, by Drug Class
13.4.10.4. Market Revenue and Forecast, by Line of Therapy
13.4.10.5. Market Revenue and Forecast, by Distribution Channel
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Histology
13.4.11.2. Market Revenue and Forecast, by Treatment Type
13.4.11.3. Market Revenue and Forecast, by Drug Class
13.4.11.4. Market Revenue and Forecast, by Line of Therapy
13.4.11.5. Market Revenue and Forecast, by Distribution Channel
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Histology
13.5.2. Market Revenue and Forecast, by Treatment Type
13.5.3. Market Revenue and Forecast, by Drug Class
13.5.4. Market Revenue and Forecast, by Line of Therapy
13.5.5. Market Revenue and Forecast, by Distribution Channel
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Histology
13.5.6.2. Market Revenue and Forecast, by Treatment Type
13.5.6.3. Market Revenue and Forecast, by Drug Class
13.5.6.4. Market Revenue and Forecast, by Line of Therapy
13.5.7. Market Revenue and Forecast, by Distribution Channel
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Histology
13.5.8.2. Market Revenue and Forecast, by Treatment Type
13.5.8.3. Market Revenue and Forecast, by Drug Class
13.5.8.4. Market Revenue and Forecast, by Line of Therapy
13.5.8.5. Market Revenue and Forecast, by Distribution Channel
14.1. F. Hoffmann-La Roche Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Bristol-Myers Squibb Company
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Pfizer Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. AstraZeneca
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Novartis AG
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. GlaxoSmithKline
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bayer AG
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. AstraZeneca
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Syneos Health
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Boehringer Ingelheim GmbH
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
